Table 6

Characteristics of the studies, pharmacokinetics and dose recommendations of isolated studies on cefotaxime

StudynPNAWeightStudy designGroupModelModalityAdministered doseVdCLt1/2 (hours)Recommended dose
Ahsman et al,26 the Netherlands373.3 (0.67–199)3.5 (2.0–6.2)P
1 group
Neonates1-compartment with NONMEMVV–VA50 mg/kg every 12 hours (PNA <1 week)
50 mg/kg every 8 hours (1<PNA<4 weeks)
37.5 mg/kg every 6 hours (PNA >4 weeks)
ECMO vs non-ECMO:
1.82 L vs 0.68–1.14 L
ECMO vs non-ECMO:
0.36 L/hour vs 0.20–0.55 L/hour
3.5 hoursThe standard cefotaxime dose regimen provides a sufficiently high t>MIC in infants undergoing ECMO.
  • Boldfaced fonts represent comparisons with controls within the same study. In other studies, they represent comparisons with non-ECMO neonates from a different published study.

  • CL, clearance; ECMO, extracorporeal membrane oxygenation; MIC, minimum inhibitor concentration; NONMEM, non-linear mixed-effects modelling; P, prospective; PNA, postnatal age; t1/2, elimination half-life; VA, veno-arterial; Vd, volume of distribution; VV, veno-venous.